$Efficacy of vericiguat in patients with chronic heart failure and reduced ejection fraction: a prospective observational study$

Efficacy of vericiguat in patients with chronic heart failure and reduced ejection fraction: a prospective observational study

Abstract Objectives This study aims to evaluate the therapeutic effect of Vericiguat through cardiopulmonary exercise testing (CPET) in patients with chronic heart failure and reduced ejection fraction (HFrEF). Methods A prospective observational study was conducted from May 2022 to May 2023, focusi...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yinge Zhan, Liu Li, Jie Zhou, Yishan Ma, Xuchong Guan, Suo Wang, Ya Chang
Format:	Article
Language:	English
Published:	BMC 2025-02-01
Series:	BMC Cardiovascular Disorders
Subjects:	Vericiguat Heart failure with reduced ejection fraction Cardiopulmonary exercise testing
Online Access:	https://doi.org/10.1186/s12872-025-04477-2
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Elevating Expectations: Vericiguat in Heart Failure with Reduced Ejection Fraction
by: Pushpraj Patel, et al.
Published: (2024-12-01)

Clinical profile of an unselected population with heart failure treated with vericiguat in real life: differences with the VICTORIA trial
by: Alberto Esteban-Fernández, et al.
Published: (2025-01-01)

Heart failure with mildly reduced ejection fraction: retrospective study of ejection fraction trajectory risk
by: Robert J.H. Miller, et al.
Published: (2022-06-01)

Clinical characteristics and outcomes in Asian patients with heart failure with mildly reduced ejection fraction
by: Julian Cheong Kiat Tay, et al.
Published: (2024-07-01)

Tailored BEST Exercise Protocol in Heart Failure Rehabilitation
by: Kevin Triangto, et al.
Published: (2025-01-01)

Economic impact of heart failure with preserved ejection fraction: insights from the ALDO‐DHF trial
by: Djawid Hashemi, et al.
Published: (2020-06-01)

Rehospitalization burden and morbidity risk in patients with heart failure with mid‐range ejection fraction
by: Enrique Santas, et al.
Published: (2020-06-01)

Sacubitril/valsartan in patients with heart failure with reduced ejection fraction with end‐stage of renal disease
by: Seonhwa Lee, et al.
Published: (2020-06-01)

Improved cardiac and venous pressures during hospital stay in patients with acute heart failure: an echocardiography and biomarkers study
by: Eiichi Akiyama, et al.
Published: (2020-06-01)

Electrocardiography-based artificial intelligence predicts the upcoming future of heart failure with mildly reduced ejection fraction
by: Dae-Young Kim, et al.
Published: (2025-02-01)

Challenges in the diagnosis of heart failure with preserved ejection fraction in individuals with obesity
by: Bas M. van Dalen, et al.
Published: (2025-02-01)

Prevalence and prognostic value of ventricular conduction delay in heart failure with preserved ejection fraction
by: Anouk Achten, et al.
Published: (2025-04-01)

Clinical characteristics and frailty status in heart failure with preserved vs. reduced ejection fraction
by: Tomoyuki Hamada, et al.
Published: (2022-06-01)

Impact of Initial Heart Rate, Diastolic Pressure, and Pulse Pressure on Prognostic Outcomes in Heart Failure Patients with Mildly Reduced Ejection Fraction
by: Hu H, et al.
Published: (2025-01-01)

Assessment of Left Ventricular Reverse Remodeling by Echocardiography After 90 Days of Sacubitril/Valsartan Therapy in Patients of Heart Failure with Reduced Ejection Fraction
by: Akshay Pawar, et al.
Published: (2024-12-01)

Two-hit mouse model of heart failure with preserved ejection fraction combining diet-induced obesity and renin-mediated hypertension
by: Justin H. Berger, et al.
Published: (2025-01-01)

Advanced heart failure: guideline‐directed medical therapy, diuretics, inotropes, and palliative care
by: Daniela Tomasoni, et al.
Published: (2022-06-01)

Sacubitril/valsartan on right ventricular-pulmonary artery coupling and albumin-bilirubin score in heart failure in Chinese patients with reduced ejection fraction
by: Yanan Shi, et al.
Published: (2025-01-01)

Association between prognosis and the use of angiotensin‐converting enzyme inhibitors and/or angiotensin II receptor blockers in frail patients with heart failure with preserved ejection fraction
by: Akihiro Sunaga, et al.
Published: (2022-06-01)

Safety and efficacy of catheter ablation in atrial fibrillation patients with heart failure with preserved ejection fraction
by: Songbing Long, et al.
Published: (2025-01-01)

Clinical study on the treatment of chronic heart failure with a novel D‐shant atrium shunt device
by: Xiaoke Shang, et al.
Published: (2022-06-01)

AdipoRon ameliorates the progression of heart failure with preserved ejection fraction via mitigating lipid accumulation and fibrosis
by: Wuping Tan, et al.
Published: (2025-02-01)

The Usefulness of Soluble ST2 Concentration in Heart Failure with Reduced Ejection Fraction to Predict Severe Impairment in Exercise Capacity Assessed in Cardiopulmonary Exercise Testing
by: Magdalena Dudek, et al.
Published: (2024-12-01)

Daily home monitoring of potassium, creatinine, and estimated plasma volume in heart failure post‐discharge
by: Patrick Rossignol, et al.
Published: (2020-06-01)

Chronic obstructive pulmonary disease and heart failure in real life: the tip of the iceberg in the sea of comorbidities. A prospective observational study
by: Ombretta Para, et al.
Published: (2025-02-01)

Characteristics and Outcomes of Heart Failure Outpatients with Improvement in Ejection Fraction in Qatar
by: Rasha Kaddoura, et al.
Published: (2024-07-01)

Personalized approach in the management of women with heart failure with preserved ejection fraction and carbohydrate metabolism disorders
by: L.R. Petrovska, et al.
Published: (2024-12-01)

Cardiac manifestation of phenylketonuria in adulthood
by: Péter Homródi, et al.
Published: (2024-12-01)

Short‐term echocardiographic evaluation by global longitudinal strain in patients with heart failure treated with sacubitril/valsartan
by: Simone Mazzetti, et al.
Published: (2020-06-01)

Sodium‐glucose cotransporter‐2 inhibitors in heart failure: an updated meta‐analysis
by: Yang Cao, et al.
Published: (2022-06-01)

Association between insulin resistance indices and outcomes in patients with heart failure with preserved ejection fraction
by: Weicheng Ni, et al.
Published: (2025-01-01)

The role of glucagon-like peptide-1 receptor (GLP-1R) agonists in enhancing endothelial function: a potential avenue for improving heart failure with preserved ejection fraction (HFpEF)
by: Darshan Hullon, et al.
Published: (2025-02-01)

Effect of immunomodulation on cardiac remodelling and outcomes in heart failure: a quantitative synthesis of the literature
by: Navkaranbir S. Bajaj, et al.
Published: (2020-06-01)

Effect of atrial high-rate episodes (AHREs) on functional status and quality of life (QoL) in heart failure—cardiac resynchronization therapy population
by: Lamyaa Elsayed Allam, et al.
Published: (2025-02-01)

Características clínicas y tratamiento farmacológico de los pacientes con insuficiencia cardíaca en una cohorte de atención primaria
by: Maria Giner-Sorian, et al.
Published: (2025-07-01)

Progress in Managing Heart Failure: an in-depth Review of Sacubitril/Valsartan Combination Therapy
by: Neeraj Hiremath, et al.
Published: (2024-04-01)

Changes of the quality of life and efficiency criteria of coronary artery bypass grafting in patients with stable coronary artery disease and preserved left ventricular ejection fraction
by: Yu.A. Borkhalenko, et al.
Published: (2018-06-01)

Minute ventilation in cardiorespiratory exercise and its relationship with ventricular ejection fraction
by: Alirio Bastidas-Goyes, et al.
Published: (2024-07-01)

Advanced heart failure with reduced ejection fraction at a young age: how long can we wait?
by: Arnold Péter Ráduly, et al.
Published: (2024-12-01)

Exploring the association between tissue sodium content, heart failure subtypes, and symptom burden: insights from magnetic resonance imaging
by: Djawid Hashemi, et al.
Published: (2025-01-01)